The Predictive Value of CHFR Methylation for Chemotherapy Response and Prognosis in Cancer Patients: a Systematic Review and Meta-analysis

Zhuo Zhang,Wenjia Zhang,Qian Xiang,Qianxin Liu,Hanxu Zhang,Xiaodan Zhang,Yimin Cui
DOI: https://doi.org/10.21203/rs.3.rs-1417277/v1
2022-01-01
Abstract:Abstract Purpose: CHFR (checkpoint with FHA and RING finger) methylation is a promising biomarker of treatment response and cancer prognosis, whereas the predictive role of it remains controversial. Thus, this meta-analysis aimed to quantify the predictive impact of this biomarker in cancer patients.Methods: PubMed, Embase, Cochrane Library and ClinicalTrials.gov. were searched to identify studies that assessed the association between CHFR methylation and clinical outcomes in patients with cancer. Treatment response was the primary endpoint, and overall survival (OS) and recurrence were the secondary endpoints.Results: Thirteen studies with 2185 cancer patients met the inclusion criteria were included. Our study showed that CHFR methylation was not associated with the chemotherapy response (odds ratio = 0.93, 95% confidence interval [CI]: 0.38–2.31, P =0.88). As for OS, we found no statistically significant association either (hazard ratio [HR] = 1.14; 95% CI: 0.86–1.50, P = 0.36), except in patients treated with surgery alone (HR = 1.37; 95% CI: 1.06-1.77, P = 0.02). Moreover, CHFR methylation was significantly associated with recurrence (HR = 2.01; 95% CI: 1.25–3.25, P=0.004).Conclusion: Our study indicates that CHFR methylation cannot be a predictive factor for response to chemotherapy, but might be a biomarker of OS and recurrence in cancer patient. Future studies should be conducted to reduce confounding and explore the mechanism.
What problem does this paper attempt to address?